Deepen understanding through next-generation sequencing
Identify genetic abnormalities for targeted treatment
Lung cancer is the leading cause of cancer-related death in the United States, and patients typically respond poorly to traditional chemotherapy. More than 80% of lung cancer cases are classified as non-small cell lung cancer (NSCLC).
Individuals with advanced disease should undergo molecular testing to identify genetic abnormalities that may predict response to targeted therapies. Therapy selection in patients with lung cancer is critical to achieving the best outcomes.
Our targeted lung cancer panel assesses for mutations in 12 genes and rearrangements in seven genes, including those recommended by the National Comprehensive Cancer Network: EGFR, ROS1, BRAF, and ALK. The results of this panel ensure that physicians have the information they need to target therapy for their patient. This genetic information also can be useful in prognosis.
Learn more about our full suite of MayoComplete next-generation sequencing panels for hematologic and oncologic conditions.
A Test in Focus
Ying-Chun Lo, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated lung panel can better guide clinical decision-making, particularly about targeted lung cancer therapies.
More answers for more patients
Lung cancer specimens are small and can vary in tumor content. Obtaining enough tissue for multiple molecular and histological tests has historically created a significant challenge for pathologists in testing patients for clinically actionable mutations as recommended.
Our lung cancer-specific NGS panel includes only clinically relevant markers, allowing for accurate and timely results. We have optimized specimen requirements by reducing the amount of formalin-fixed, paraffin-embedded (FFPE) tissue and accepting cytology, which allows more patients to receive results.
Resistance mutation testing
Based on recently released guidelines from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology, patients in relapse after an initial response to EGFR-targeted therapies should be tested for the acquired T790M mutation in the EGFR gene.